DeepMed Research

Corcept Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 352

Market Cap: $3.6B

Website

Clinical Trials

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Phase 1

Not yet recruiting

Conditions: Nonalcoholic Steatohepatitis (NASH)
Non-alcoholic Fatty Liver Disease (NAFLD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Interventions: Drug: Miricorilant

First Posted Date: 2025-04-27

Last Posted Date: 2025-04-27

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 8

Registration Number: NCT06947304

Locations: 🇺🇸
University of Missouri, Columbia, Missouri, United States

Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Dazucorilant

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 19

Registration Number: NCT06928779

Locations: 🇺🇸
Site 2, Rialto, California, United States
🇺🇸
Site 1, Miami, Florida, United States

Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Phase 2

Recruiting

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasms

Interventions: Drug: Relacorilant 150 mg once daily (QD)
Drug: Nab-paclitaxel 80 mg/m^2
Drug: Bevacizumab 10 mg/kg

First Posted Date: 2025-04-02

Last Posted Date: 2025-05-08

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 90

Registration Number: NCT06906341

Locations: 🇺🇸
292, Albuquerque, New Mexico, United States
🇺🇸
517, Eugene, Oregon, United States
🇺🇸
304, Centerville, Ohio, United States

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

Recruiting

Conditions: Resistant Hypertension
Hypercortisolism

First Posted Date: 2025-02-17

Last Posted Date: 2025-05-21

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 1000

Registration Number: NCT06829537

Locations: 🇺🇸
Site 436, Cincinnati, Ohio, United States
🇺🇸
Site 456, Austin, Texas, United States
🇺🇸
Site 370, Dallas, Texas, United States

and more 5 locations

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

Phase 1

Active, not recruiting

Conditions: Healthy Adults

Interventions: Drug: Dazucorilant
Drug: Itraconazole

First Posted Date: 2024-07-11

Last Posted Date: 2025-03-13

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 21

Registration Number: NCT06495944

Locations: 🇺🇸
Site 01, Baltimore, Maryland, United States

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Phase 2

Recruiting

Conditions: Nonalcoholic Steatohepatitis (NASH)
Metabolic Dysfunction-associated Steatohepatitis (MASH)

Interventions: Drug: Placebo (Cohort B)
Drug: Miricorilant (Cohort A)
Drug: Placebo (Cohort A)
Drug: Miricorilant (Cohort B)

First Posted Date: 2023-10-30

Last Posted Date: 2024-12-10

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 195

Registration Number: NCT06108219

Locations: 🇺🇸
Site #475, Largo, Florida, United States
🇺🇸
Site #207, Chandler, Arizona, United States
🇺🇸
Site #209, Tucson, Arizona, United States

and more 42 locations

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CORT125134

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 8

Registration Number: NCT06094712

Locations: 🇺🇸
Jasper Clinic, Kalamazoo, Michigan, United States

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CORT125134 150 mg
Drug: CORT125134 dose to be determined
Drug: CORT125134 250 mg

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 32

Registration Number: NCT06094790

Locations: 🇺🇸
Quotient Sciences, Miami, Inc., Miami, Florida, United States

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Relacorilant

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 30

Registration Number: NCT06094725

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Relacorilant after a high-fat meal
Drug: Relacorilant after a low-fat meal
Drug: Relacorilant under fasted conditions

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 30

Registration Number: NCT06094738

Locations: 🇺🇸
inVentiv Health Clinical Research Services LLC, Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy